XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
NCT05184322 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87
Last updated 2025-09-10
Summary
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
Conditions
Interventions
- DRUG
-
T2026
Once daily for 15 days.
- DRUG
-
Once daily for 15 days.
- DRUG
-
Oral ecnoglutide tablet
Once daily for 6 weeks.
- DRUG
-
Oral ecnoglutide tablet
Once daily and titrated up in concentration to once every week during maintenance period.
- DRUG
-
Oral ecnoglutide tablet
Once daily for 15 days.
- DRUG
-
Oral ecnoglutide tablet
Once daily for 15 days.
- DRUG
-
Oral ecnoglutide tablet
Once daily for 15 days.
- DRUG
-
Oral ecnoglutide tablet
Once daily for 15 days.
- DRUG
-
T2026
Once daily for 6 weeks.
- DRUG
-
Once daily for 6 weeks.
- DRUG
-
T2026
Once daily to once weekly for 12 weeks.
- DRUG
-
Once daily to once weekly for 12 weeks.
Sponsors & Collaborators
-
Hangzhou Sciwind Biosciences Co., Ltd.
collaborator INDUSTRY -
Sciwind Biosciences USA Co., Ltd.
collaborator INDUSTRY -
Sciwind Biosciences APAC CO Pty. Ltd.
lead INDUSTRY
Principal Investigators
-
Richard Friend · Nucleus Network Brisbane Clinic
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-04-12
- Primary Completion
- 2024-07-13
- Completion
- 2025-03-25
Countries
- Australia
Study Locations
More Related Trials
-
Dose Ranging Study of Albiglutide in Japanese Subjects
NCT01098461 ·Status: COMPLETED ·Phase: PHASE2
-
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
NCT02057172 ·Status: COMPLETED ·Phase: PHASE2
-
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
NCT01511900 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
NCT04591626 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
NCT06988553 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
NCT03994549 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017 ·Status: COMPLETED ·Phase: PHASE3
-
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
NCT01516476 ·Status: TERMINATED ·Phase: PHASE2
-
The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
NCT01342042 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
NCT04504370 ·Status: COMPLETED ·Phase: PHASE3
-
A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532
NCT01369277 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.
NCT07234864 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
NCT05363774 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
NCT04014023 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT07065032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
NCT01965496 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
NCT07073170 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
NCT04632862 ·Status: COMPLETED ·Phase: PHASE3
-
A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.
NCT00682097 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
NCT01029704 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
NCT02916706 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Safety of Supaglutide in Healthy Participants
NCT03745885 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
NCT03848793 ·Status: COMPLETED ·Phase: PHASE2
-
Therapeutic Exploratory Study of CWP-0403
NCT00888719 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
NCT04654390 ·Status: COMPLETED ·Phase: PHASE3